Aclaris Therapeutics ACRS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.66M-5.6% | $19.96M-18.8% | $25.26M-47.0% | $25.4M+11.2% | $30.36M-15.3% | ||
| $76.76M+2.4% | $70.79M-20.5% | $70.66M-11.8% | $74.4M-15.7% | $74.96M-18.8% | ||
| $110.23M+1.3% | $96.32M-23.5% | $100.59M-24.0% | $104.2M-11.4% | $108.79M-19.6% | ||
| $750K-20.4% | $761K-24.5% | $811K-28.4% | $868K-32.9% | $942K-38.5% | ||
| $198.72M+0.3% | $160.46M-27.2% | $175.53M-3.8% | $189.15M+17.4% | $198.09M+13.8% | ||
| $14.73M+132% | $13.16M+181% | $9.19M+19.9% | $8.8M+21.0% | $6.35M-41.2% | ||
| $3.97M— | $3.94M— | $3.93M— | $3.91M— | —— | ||
| $27.37M+27.2% | $28.65M-9.3% | $25.63M+36.2% | $26.84M+71.1% | $21.51M+7.1% | ||
| $55.07M+1.9% | $57.38M-11.4% | $55.43M+6.1% | $57.41M+111% | $54.03M+68.6% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$987.61M-7.6% | -$967.78M-7.2% | -$947.99M-17.6% | -$933.38M-16.9% | -$917.95M-16.5% | ||
| $143.65M-0.3% | $103.08M-33.7% | $120.1M-7.7% | $131.74M-1.6% | $144.07M+1.4% | ||
| $198.72M+0.3% | $160.46M-27.2% | $175.53M-3.8% | $189.15M+17.4% | $198.09M+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's total assets?
- Aclaris Therapeutics (ACRS) holds $198.7M in total assets, up 0.3% year over year.
- How much debt does Aclaris Therapeutics have?
- Aclaris Therapeutics carries $2.0M in total debt against $143.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Aclaris Therapeutics have?
- Aclaris Therapeutics holds $28.7M in cash and equivalents.
- Can Aclaris Therapeutics cover its short-term obligations?
- Its current ratio is 4.03 — current assets exceed current liabilities.
- Where does Aclaris Therapeutics's balance sheet data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
